<DOC>
	<DOCNO>NCT02083354</DOCNO>
	<brief_summary>This single-arm , open-label , multi-center , Phase II study evaluate dabrafenib trametinib combination therapy subject BRAF V600 mutation-positive , unresectable metastatic Acral lentiginous cutaneous melanoma . This study evaluate objective response rate ( ORR ) , progression free survival ( PFS ) , duration response , overall survival ( OS ) , safety efficacy , ass steady state ( subject ) exposure dabrafenib , dabrafenib metabolite , trametinib characterize population pharmacokinetics ( PK ) pharmacodynamics ( PD ) dabrafenib trametinib . Subjects enrol receive dabrafenib 150 milligram ( mg ) orally twice daily trametinib 2 mg orally daily . Treatment continue disease progression , death , unacceptable toxicity , withdrawal consent , study closure . After treatment discontinuation , subject follow survival disease progression applicable .</brief_summary>
	<brief_title>Study Investigate Objective Response Rate Dabrafenib Combination With Trametinib Subjects With BRAF V600 Mutation-Positive Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Signed write informed consent , include compliance requirement restriction list consent form . &gt; =18 year age . Histologically confirm acral lentiginous cutaneous melanoma either Stage IIIC ( unresectable ) Stage IV ( metastatic ) , BRAF V600 mutationpositive . The test conduct designated central laboratory . Measurable disease ( i.e. , present least one measurable lesion ) RECIST version1.1 . Performance status score 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale . All prior anticancer treatmentrelated toxicity ( except alopecia laboratory value ) must &lt; =Grade 1 accord Common Terminology Criteria Adverse Events version 4 ( CTCAE version 4.0 ) time enrolment . Able swallow retain oral medication must clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel . Women childbearing potential must negative serum pregnancy test within 14 day first dose study treatment agree use effective contraception , 14 day prior enrolment , throughout treatment period 4 month last dose study treatment . Adequate baseline organ function define : Absolute Neutrophil Count : &gt; = 1.2 Ã— 10^9/liter ( L ) ; Hemoglobin : &gt; =9 gram ( g ) /deciliter ( dL ) ; Platelet count : &gt; =100 x 10^9/L ; Prothrombin Time/International Normalized Ratio ( INR ) ( Subjects receive anticoagulation treatment may allow participate INR establish within therapeutic range prior enrolment ) Partial Thromboplastin Time : &lt; =1.5 x Upper Limit Normal ( ULN ) ; Albumin : &gt; =2.5 g/dL ; Total bilirubin : &lt; =1.5 x ULN ; Aspartate aminotransferase Alanine aminotransferase : &lt; =2.5 x ULN ; Calculated creatinine clearance ( Calculate creatinine clearance use standard CockcroftGault formula ) : &gt; =50 milliliter ( mL ) / minute ( min ) ; Left Ventricular Ejection Fraction ( LVEF ) ( ECHO scan must use throughout study ) : &gt; = Lower limit normal ( LLN ) ECHO . Subjects East Asian origin . Primary mucosal ocular melanoma . Prior treatment BRAF inhibitor ( include limit dabrafenib , vemurafenib , LGX818 , XL281/BMS908662 ) MEK inhibitor ( include limit trametinib , AZD6244 , RDEA119 ) . Any major surgery , extensive radiotherapy , chemotherapy delay toxicity , biologic anticancer therapy , immuno anticancer therapy within 21 day prior enrolment /or daily weekly chemotherapy without potential delayed toxicity within 14 day prior enrolment . ( Note : Ipilimumab , pembrolizumab nivolumab treatment must end least 8 week prior enrollment ) . Taken investigational drug within 28 day 5 halflives ( minimum 14 day ) , whichever short , prior enrolment . ( Note : case ipilimuamb , pembrolizmab nivolumab investigational drug region country , case PDL1 antibody , investigational treatment must end least 8 week prior enrollment ) . Current use prohibit medication . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study treatment , excipients , and/or dimethyl sulfoxide ( DMSO ) . A history Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( subject laboratory evidence clear HBV and/or HCV permit ) . Leptomeningeal brain metastasis metastases cause spinal cord compression : symptomatic untreated stable 3 month ( must document imaging ) require corticosteroid . Subjects stable dose corticosteroid &gt; 1 month replacement dose , corticosteroid least 2 week enrol approval medical monitor . Subjects must also enzymeinducing anticonvulsant &gt; 4 week . History another malignancy . Exception : Subjects diseasefree 3 year , study enrolment exception . Exception : Subjects history completely resect nonmelanoma skin cancer , subject indolent second malignancy eligible approval sponsor 's medical monitor . History malignancy confirm activate RAS mutation time . Note : Prospective RAS testing require . However , result previous RAS test know , must use assess eligibility Any serious unstable preexist medical condition ( aside malignancy exception specify ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent , compliance study procedure . A history evidence cardiovascular risk include follow : Current LVEF &lt; Institutional LLN ; A QTc interval correct heart rate &gt; =480 millisecond ( msec ) ( use Bazett 's formula ) ; A history evidence current clinically significant uncontrolled arrhythmia . Clarification : Subjects atrial fibrillation control &gt; 30 day prior dose eligible ; A history acute coronary syndrome ( include myocardial infarction unstable angina ) , coronary angioplasty , stenting within 6 month prior randomization ; A history evidence current &gt; =Class II congestive heart failure define New York Heart Association ( NYHA ) guideline ; Patients intracardiac defibrillator ; Treatment refractory hypertension define blood pressure systolic &gt; 140 millimeter mercury ( mmHg ) and/or diastolic &gt; 90 mmHg control antihypertensive therapy ; Known cardiac metastasis ; Abnormal cardiac valve morphology ( &gt; =grade 2 ) document echocardiogram ( subject grade 1 abnormality [ i.e. , mild regurgitation/stenosis ] enter study ) . Subjects moderate valvular thickening enter study . Uncorrectable electrolyte abnormality ( e.g . hypokalaemia , hypomagnesaemia , hypocalcaemia determine blood chemistry ) , long QT syndrome take medicinal product know prolong QT interval . A history current evidence retinal vein occlusion ( RVO ) . Pregnant nursing female . History current diagnosis interstitial lung disease pneumonitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>melanoma</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>trametinib</keyword>
</DOC>